Two Sigma Advisers
TLIS

Two Sigma Advisers’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Two Sigma Advisers’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,587
Closed -$34K – 2932
2022
Q1 		$34K Sell
1,587
-73
-4% -$2.53K ﹤0.01% 2628
2021
Q4 		$100K Buy
+1,660
New +$124K ﹤0.01% 2404

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's TLIS Position: Q2 2022 in Review

Two Sigma Advisers sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 1,587 shares — an estimated $34K sold.

Two Sigma Advisers first reported a position in TLIS in Q4 2021 and held it in 2 quarters. The position peaked at $100K in Q4 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Two Sigma Advisers reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 1,587 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $34K.
  • Two Sigma Advisers first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Talis Biomedical Corporation Common Stock position peaked at $100K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.